Tag Archives: GLP-1
GLP-1 RAs in Lumbar Fusion: 7 Cohorts Reviewed
GLP-1 receptor agonist exposure before lumbar fusion showed no statistically significant increase in the reviewed postoperative outcomes.
Semaglutide in HIV: 108 Participants, 32 Weeks
Semaglutide did not change the trial's measured vascular markers over 32 weeks, while ASCVD risk score and hsCRP differed from placebo.
Semaglutide: SELECT Results by Frailty Status
Semaglutide showed no detectable difference in SELECT cardiovascular results across baseline frailty categories in a new post-hoc analysis.
Tirzepatide in HS: Signals From a TriNetX Cohort
Tirzepatide or GLP-1RA exposure was associated with different two-year outcomes in a matched hidradenitis suppurativa cohort.
GLP-1 Receptor Agonists: One Circuit, Two Effects
GLP-1 receptor agonists engaged one brainstem circuit for both reduced feeding and aversion in a new preclinical study.
Tirzepatide: 22,104 Matched Bariatric-Surgery Patients
Tirzepatide or GLP-1RA use before bariatric surgery was associated with fewer 90-day cardiorenal events in 22,104 matched patients.
GLP-1 Receptor Agonists: 44 Adolescent Records
GLP-1 receptor agonists were not linked to higher short-term suicidality scores in a small retrospective review of 44 adolescents.
GLP-1 and Lean Mass: 60 Studies, 1.25m People
GLP-1 evidence from 60 studies found lower lean mass, but no significant bone or joint effect and low certainty for muscle implications.
GLP-1 in Resistant Hypertension: Equal BP, 4,153 Pairs
GLP-1 agonists and mineralocorticoid antagonists cut blood pressure almost equally in 4,153 matched pairs, yet the hard outcomes separated sharply.
GLP-1: WHO Guidelines, 1 Billion People, 3 Industries
GLP-1 now has a WHO guideline, and a Science editorial names the three industries competing around it: pharmaceutical, food and wellness.